Moberg Pharma AB (publ) (MOB.ST)
- Previous Close
7.40 - Open
7.51 - Bid 7.32 x --
- Ask 7.45 x --
- Day's Range
7.27 - 7.65 - 52 Week Range
6.34 - 39.78 - Volume
135,300 - Avg. Volume
127,571 - Market Cap (intraday)
343.196M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-6.74 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
11.10
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
www.mobergpharma.se10
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MOB.ST
View MorePerformance Overview: MOB.ST
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOB.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOB.ST
View MoreValuation Measures
Market Cap
345.53M
Enterprise Value
57.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.35
Price/Book (mrq)
0.50
Enterprise Value/Revenue
5.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.29%
Return on Equity (ttm)
-39.32%
Revenue (ttm)
9.81M
Net Income Avi to Common (ttm)
-255.11M
Diluted EPS (ttm)
-6.74
Balance Sheet and Cash Flow
Total Cash (mrq)
293.29M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
27.25M